Showing results (11-20 of 60) with videos related to
Sort By:
Pageof 6
The Oncologist|December 17, 2009
The case for chemotherapy only for localized Hodgkin lymphomaDavid J StrausExpert Review of Anticancer Therapy|March 1, 2006
Treatment of Burkitt lymphoma in adultsJohn Gerecitano, David J StrausJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 3, 2006
The role of PET in lymphomaYuliya S Jhanwar, David J StrausJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Acupuncture for postchemotherapy fatigue: a phase II studyAndrew J Vickers, David J Straus, Bertha Fearon, et al.Leukemia & Lymphoma|October 12, 2019
Incidence of infectious complications with the combination of bendamustine and an anti-CD20 monoclonal antibody<sup>.</sup>Kristen M Sarlo, Brianne N Dixon, Ai Ni, et al.Journal of the American Academy of Dermatology|January 31, 2012
Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placeboH Miles Prince, Madeleine Duvic, Ann Martin, et al.Clinicoeconomics and Outcomes Research : CEOR|November 10, 2018
Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failureMachaon Bonafede, Joseph Feliciano, Qian Cai, et al.Cancer|March 17, 2007
Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphomaDavid J Straus, Madeleine Duvic, Timothy Kuzel, et al.Leukemia & Lymphoma|August 23, 2006
Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?Carol S Portlock, Owen A O'Connor, David J Straus, et al.Journal of the National Cancer Institute|February 27, 2015
Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthoodMatthew J Matasar, Jennifer S Ford, Elyn R Riedel, et al.Pageof 6